Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
TUCSON, Arizona and INGELHEIM, Germany, 19 September 2013 – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes.
As part of the agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim’s personalised medicine healthcare strategies for cancer drug development.
Companion diagnostic tests provide information that aids physicians in choosing targeted treatments for their patients based on the expected best response to therapy. By integrating the development of companion diagnostic kits and drug candidates, Boehringer Ingelheim strives to yield cancer treatments with optimised benefit risk profiles.
“We are pleased that Ventana’s commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programmes,” says Mara G. Aspinall, President, Ventana Medical Systems, Inc.
About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalised Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies.
VENTANA, the VENTANA logo, and BenchMark are trademarks of Roche.
Visit www.ventana.com to learn more.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com
SOURCE: Boehringer Ingelheim